合成,作为抗癌活性强大的巴克斯激动剂的蒙尼丁衍生物的分子对接研究
Wei-Dong Jia1, Xue Bai1,2, Qian-Qian Ma1,2
1Inner Mongolia Minzu University, Tongliao, P.R. China.
Natural product research
|November 3, 2023
概括
一种新型的诺尼丁衍生物,7a,通过激活Bax,对肺癌细胞表现出强大的抗癌活性. 这种化合物在肺癌治疗中表现出显著的疗效和潜力.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 甲诺丁是一种巴克斯激动剂,表现出抗癌性质.
- 识别新型巴克斯激动剂对于开发新的癌症疗法至关重要.
研究的目的:
- 合成和评估新型的诺尼丁衍生物作为潜在的巴克斯激动剂用于抗癌应用.
- 评估这些衍生物在肺癌细胞系中的抗癌活性和作用机制.
主要方法:
- 合成了18种新型的莫尼尼丁衍生物.
- 在A549 (肺癌) 和Beas-2b (正常支气管上皮) 细胞系中评估抗癌活性.
- 西方斑点和免疫光试验用于调查与亡相关的蛋白质表达 (Bcl-2,Bax).
主要成果:
- 化合物7a对A549细胞表现出最强的抑制作用 (IC50 = 0.87μM),显示出明显更高的疗效,而不是formononetin和 doxorubicin.
- 化合物7a对Beas-2b细胞没有明显的毒性.
- 7a通过降低Bcl-2的调节和提高Bax蛋白表达的调节促进了A549的亡.
结论:
- 化合物7a是一种强大的巴克斯激动剂,对肺癌具有显著的抗癌活性.
- 7a显示出作为预防和治疗肺癌的化合物的潜力.
- 该机制涉及调节与亡相关的蛋白质,特别是Bax和Bcl-2.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Structure-Activity Relationships and Drug Design
734
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
734
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.1K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.1K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K


